BCMA targeted therapies market seen reaching $44.29 billion by 2030

The market for B-cell maturation antigen targeted therapies is projected to jump from $15.09 billion in 2025 to $18.75 billion in 2026, driven by multiple myeloma demand and faster adoption of next-generation immunotherapies. The Business Research Company says North America led the market in 2025, while the long-term outlook points to broad growth through 2030.

Why it matters: - BCMA targeted therapies are becoming a bigger part of multiple myeloma treatment as drug makers push more precise options for relapsed and refractory disease. - The market's rapid growth signals rising demand for next-generation immunotherapies, including CAR-T, bispecific antibodies and antibody-drug conjugates. - Multiple myeloma incidence continues to support demand for targeted treatments.

What happened: - The Business Research Company published its B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report estimates the BCMA targeted therapies market will rise from $15.09 billion in 2025 to $18.75 billion in 2026. - The report projects the market will reach $44.29 billion by 2030. - North America held the largest share of the market in 2025.

The details: - BCMA targeted therapies are designed to bind to BCMA, a protein on mature B-cells and plasma cells. - BCMA belongs to the tumor necrosis factor receptor superfamily. - BCMA helps regulate the development, survival and differentiation of B-cells into plasma cells. - The report links 2025-2026 growth to deeper understanding of BCMA biology, higher multiple myeloma prevalence, early clinical wins, more hematology oncology centers and higher investment in immuno-oncology research. - The forecast through 2030 is driven by more approvals for next-generation BCMA therapies, stronger demand for off-the-shelf immunotherapies, broader combination regimens, a focus on durable remission and more AI-driven patient stratification. - Key trends include wider CAR-T use, advances in bispecific antibody platforms, greater use of BCMA-targeted antibody-drug conjugates, more personalized immunotherapy protocols and closer attention to relapsed and refractory multiple myeloma. - The report says multiple myeloma cases are rising because of an aging population, better diagnostics and uneven access to care. - The American Cancer Society reported in August 2024 that the U.S. had about 35,780 new multiple myeloma cases in 2024, including 19,520 in men and 16,260 in women. - The American Cancer Society also projected about 12,540 deaths in 2024, including 7,020 among men and 5,520 among women. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 market report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast suggests BCMA therapies are moving from a niche oncology category into a larger commercial market as treatment standards evolve. - The emphasis on off-the-shelf immunotherapies and combination regimens points to a push for easier deployment and deeper responses than earlier cell-therapy approaches alone. - North America's lead in 2025 likely reflects earlier adoption of advanced cancer therapies and stronger research infrastructure.

What's next: - More BCMA therapy approvals could expand the market beyond current leaders. - Wider use of AI-based patient stratification may help match therapies to patients more efficiently. - Competition is likely to intensify as companies develop CAR-T, bispecific and ADC approaches for multiple myeloma.

The bottom line: - BCMA targeted therapies are emerging as one of the fastest-growing segments in multiple myeloma treatment, with the market forecast to nearly double from 2026 to 2030.